All Activity

This is a truly good site post. Not too many people would actually, the way you just did. I am really impressed that there is so much information about this subject that have been uncovered and you’ve done your best, with so much class. If wanted to know more about green smoke reviews, than by all means come in and check our stuff. mawartoto

This can be a excellent post, Many thanks with regard to providing me personally these details. Maintain publishing. google ppc advertising agency

It's which means that amazing together with inspiring. We really enjoy any designs together with whoever should get it all during the post shall be grinning. google ppc advertising agency

Thanks For sharing this Superb article.I use this Article to show my assignment in college.it is useful For me Great Work. koitoto I admire this article for the well-researched content and excellent wording. I got so involved in this material that I couldn’t stop reading. I am impressed with your work and skill. Thank you so much. industrial tank cleaner

Excellent article. Very interesting to read. I really love to read such a nice article. Thanks! keep rocking. Gartenpools

I think this is an informative post and it is very useful and knowledgeable. therefore, I would like to thank you for the efforts you have made in writing this article. 벳톡 가입주소

This specific is a great article My spouse and i witnessed due to talk about the idea. It is definitely precisely what I want to to view expect throughout potential you can proceed pertaining to expressing a real exceptional article. koi toto

I’m influenced using the surpassing as well as preachy itemizing that you simply provide such small timing. koi toto

Marijuana Moment’s push request for public and media livestream access to the historic federal cannabis rescheduling hearings starting next week is being joined by a member of Congress and other journalists. Rep. Steve Cohen (D-TN) on Friday sent a letter to the head of the Drug Enforcement Administration (DEA), saying that the marijuana rescheduling process that is underway is “historic.” “I write to request that the hearings be made accessible to the public in real time,” Cohen wrote to DEA administrator Terrance Cole. “Live streaming technologies have become ubiquitous and a common way Americans interact with the government. In late 2024, when undertaking a similar effort, your agency allowed the proceedings to be livestreamed because of ‘the public interest in this matter’ and followed from your agency’s ‘commitment to conducting a transparent proceeding.’ “I do not see any reason why that rationale wouldn’t hold today, especially regarding such an important and impactful matter,” the congressman wrote. “I have long been an advocate for transparency in court room processes and believe this is a rare opportunity to inform the public about rulemaking and administrative adjudication.” Cohen’s letter follows a pair of requests that Marijuana Moment’s lawyer submitted to Cole and to DEA Chief Administrative Law Judge Derek Julius to request livestreaming access to the hearing on the proposal to move cannabis from Schedule I of the Controlled Substances Act (CSA) to Schedule III—which only involves opponents of the reform as participants. Also on Friday, an attorney for Portfolio Media, Inc., which publishes Law360, sent a letter to Cole saying that it “joins in Marijuana Moment’s request” for streaming access. “Such access is consistent with both the DEA’s previous approach to this hearing and with the compelling public interest in the rescheduling of marijuana under the CSA, a potential policy shift with profound social, legal, and regulatory consequences,” the letter says. Requiring in-person attendance for observers “restricts real-time information on a consequential policy development to the handful of members of the press and public in attendance, and it deprives the press of its ability to report on that development as it unfolds,” it says. “Livestreaming is a safe, nondisruptive, straightforward means of guaranteeing meaningful public access and advancing the DEA’s stated commitment to transparency.” Separately, an attorney representing cannabis publication Cultivated Media and also on behalf of New York Times reporter Ashley Southall also sent a letter to the DEA administrator saying they “desire the ability to monitor the proceeding in real time so they may provide contemporaneous reports to their readership about the progress and focus of testimony and evidence during the hearing.” “Cultivated Media, Ashley Southall, and Marijuana Moment and all other media outlets by virtue of such livestreaming access can contemporaneously report on the issues and progress of the hearing which are matters of significant public concern pertaining to a historic hearing,” it said. DEA announced on Thursday that it would make a transcript available at the conclusion of the multi-day hearing, but Marijuana Moment attorney Joseph A. Bondy wrote in his letter on Thursday that it wouldn’t help the public follow the proceedings in real time on a daily basis. “A final transcript is useful, but it is not a substitute for livestream access. Livestreaming allows the public and press to observe the hearing as it unfolds, without vying for admittance, crowding the courtroom or affecting the proceeding,” the letter to Cole says. “Once a transcript is reviewed, corrected, and released several weeks after the testimony has been given, the opportunity for real-time observation, timely reporting, and informed public response has already passed.” “For a substantial public audience seeking serious coverage of federal cannabis policy, Marijuana Moment is an important channel through which public understanding of this proceeding occurs.” “To the extent DEA believes livestreaming is now inappropriate despite DEA’s prior directive in this rulemaking, Marijuana Moment respectfully requests a written explanation identifying the specific basis for that conclusion, including why the public-interest and transparency considerations that previously warranted livestreaming are outweighed here,” Bondy wrote. — Marijuana Moment’s journalism is made possible by readers like you who value this work enough to support us with monthly pledges on Patreon. If you rely on our reporting to stay informed about key cannabis developments, please help us keep doing this by becoming a sustaining subscriber today. Backing us at the $25/month level also gets you access to our Bill Tracker so you won’t miss any important marijuana legislation in your state. — Separately, medical cannabis advocates on Thursday sent a letter to Julius, the DEA judge who said he wouldn’t consider submissions from outside parties, also requesting livestream access. “Many patients with the greatest interest in this proceeding are unable to travel to Arlington, Virginia. Many are disabled, immunocompromised, elderly, financially constrained, or managing serious medical conditions,” the letter from Americans for Safe Access, Veterans Initiative-22, U.S. Pain Foundation, Realm of Caring, Montel Williams and other advocates says. “Even patients and advocates who can travel may not be physically able to wait in line for an uncertain chance at admission, only to be turned away once the limited seating is filled,” they wrote. “As such, the hearing may technically be open to the public, yet practically inaccessible to most.” Meanwhile, DEA said in a new filing that its witness list for the hearing includes a doctor who will provide testimony about how “medical marijuana provides a medical benefit to pain patients.” Separately, rescheduling opponents that are participating in the hearing filed statements this week previewing the anti-marijuana arguments they intend to make during the proceedings. The hearing will begin on June 29 and is set to conclude no later than July 15. Acting Attorney General Todd Blanche in April issued an order that immediately reclassified state-licensed medical cannabis, as well as marijuana products approved by the Food and Drug Administration (FDA) from Schedule I of the Controlled Substances Act (CSA) to Schedule III. Under a separate order the acting attorney general signed, the upcoming hearing will consider more comprehensively moving marijuana to Schedule III. A prior hearing process on the marijuana rescheduling process that was initiated by the Biden administration stalled last year amid litigation over alleged improper communications and witness selection. The current marijuana rescheduling process is being challenged with several lawsuits that have been consolidated by a federal appeals court. Those pieces of litigation against the cannabis reform have been filed by state attorneys general, marijuana legalization opponents and a cannabis-focused biopharmaceutical corporation. Meanwhile, the already-enacted rescheduling of state-licensed medical cannabis is already having broad impacts. The Congressional Research Service published a report on the current cannabis rescheduling move explaining that certified patients who possess medical marijuana from state-licensed dispensaries now have certain protections under Schedule III. “The order appears to authorize end users to possess marijuana for medical use without a CSA-compliant prescription,” it says. The Bureau of Alcohol, Tobacco, Firearms and Explosives (ATF) has posted a draft update to a gun purchase form to acknowledge the federally legal status of medical marijuana under rescheduling. The revised section in question notably says that only “use or possession of marijuana for recreational purposes” is federally prohibited, leaving out the prior form’s mention of medical cannabis. The U.S. Department of the Treasury and Internal Revenue Service (IRS) said they plan to issue new tax guidance for the marijuana industry following rescheduling. The reform will benefit state-licensed marijuana businesses by allowing them to take federal tax deductions they’re currently barred from under an IRS code known as 280E that doesn’t apply to Schedule III substances. Even DEA, which has long opposed cannabis legalization and was accused of stalling the rescheduling process initiative by the Biden administration, has launched a registration process for state-legal marijuana businesses to take advantage of federal benefits that come with the reform. The Department of Transportation, on the other hand, issued guidance saying that use of state-legal medical cannabis is still no excuse for a positive drug test by truck drivers, pilots and other safety-sensitive workers. A congressional committee recently voted to block federal officials from taking further steps to carry out cannabis rescheduling. Read letters to the DEA administrator about livestream access: The post Congressman And Other Media Outlets Join Marijuana Moment’s Push For DEA To Livestream Rescheduling Hearing appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

Louisiana’s governor has allowed a bill to create a psychedelic-assisted therapy pilot program to take effect without his signature. The new effort will use opioid settlement dollars to fund clinical trials aimed at developing alternative treatments such as psilocybin, ibogaine and MDMA. The Senate and House of Representatives both gave final approval to the proposal from Sen. Patrick McMath (R) in unanimous votes last month. Gov. Jeff Landry (R) chose not to sign or veto it, instead letting it go into effect without his explicit approval. The House had added MDMA to the scope of the original Senate legislation, and also made technical changes to the text. The Senate objected, however, to what supporters said was an error in the revised version, and members requested that the measure be sent to a bicameral conference committee, where that was resolved before the corrected bill came back to the floor of both chambers for final votes. Rep. Neil Riser (R), who presented the legislation to the House, said previously that the amendment adding MDMA “put us in positive correlation” with a psychedelics executive order recently signed by President Donald Trump “so that we can look at all different alternatives, including those that are beyond ibogaine that were listed it in the executive order.” He discussed psychedelics as a much-needed alternative treatment option for military veterans and others dealing with post-traumatic stress disorder (PTSD), saying that “for every soldier that’s killed in action, five commit suicide when they get home.” “So clearly, the best methodology of treatment that we’ve been using at the [Department of Veterans Affairs] or elsewhere really does not work,” he said. “There’s also the firemen and police officers that suffer from this post-traumatic stress.” Riser told colleagues that “you’ll look back on a lot of pieces of legislation that you voted on and voted for.” “This will be a piece of legislation that you will truly be proud to know that you change people’s lives,” he said. The psychedelics program would be overseen by the Louisiana Department of Health (LDH), which will be responsible for facilitating clinical trials involving substances that hold therapeutic potential. The bill says that eligible participants will include people with opioid use disorders, co-occurring substance use disorders and treatment-resistant neurological or mental health conditions. Any studies will need to go though the federal Food and Drug Administration (FDA) investigational drug approval process. Researchers will also need to be permitted by the Drug Enforcement Administration (DEA) to conduct trials involving the Schedule I controlled substances. Patients participating in the studies will need to go through mental and physical health screening, and researchers will also be required to develop processes that ensure safety and compliance, with adverse event reporting rules, training and licensing for therapists and policies for tracking and handling the psychedelics. There are also provisions authorizing academic institutions to collaborate in the clinical trials to bolster FDA approval prospects to develop prescription drugs based on psychedelics. Researchers will also be encouraged to collaborate with institutions in other states that have similar programs in place. If a drug is approved and developed as a result of the pilot program clinical trials, there will be a revenue sharing requirement. Under the bill as amended on the House floor, it says that “not less than a two and one-half percent of net sales” will go to the state, though a prior committee amendment had put that amount at 20 percent. Under SB 43 as enacted, Louisiana would participate in a national consortium for research and drug development. If a therapy does gain FDA approval, revenue tied to the intellectual property rights of that drug will go to the consortium (except for the portion specifically earmarked for Louisiana). Last year, McMath also sponsored a resolution approved by the full chamber that called for the establishment of a task force to study and make recommendations on the potential therapeutic benefits of psychedelics for veterans. — Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments. Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. — Separately, Landry also allowed a bill to let patients with terminal and irreversible conditions use medical marijuana in hospitals take effect without his signature. At the same time, however, advocates are alarmed that lawmaker passed, and the governor signed, legislation that threatens to send people to jail for up to one year if they smoke marijuana within 2,000 feet of a school property—including a college campus. Separately, a lawmaker recently filed a proposal that would create a new state task force to “study and develop findings and recommendations regarding the potential legalization of recreational marijuana.” Another Louisiana lawmaker, meanwhile, recently introduced a bill to create an adult-use marijuana legalization pilot program in the state to determine whether the reform should eventually be expanded and permanently codified. Rep. Candace Newell (D)—who has long championed legislation to end cannabis criminalization and filed a similar legal marijuana pilot program measure last session—is sponsoring what’s titled the “Adult-Use Cannabis Pilot Program Regulation and Enforcement Act.” Newell’s earlier version of the pilot program legislation didn’t advance to enactment last year, and lawmakers that session also rejected other marijuana reform proposals such as one that would have established a tax system to prepare the eventual legalization of adult-use cannabis. Photo courtesy of Mark Groeneveld. The post Louisiana Bill To Create Psychedelic Therapy Pilot Program Funded By Opioid Settlement Dollars Takes Effect Without Governor’s Signature appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

The Drug Enforcement Administration (DEA) has revealed in a new filing for the cannabis rescheduling hearing set to start on Monday that its witness list includes a doctor who will provide testimony about how “medical marijuana provides a medical benefit to pain patients.” The government’s other witness is a Food and Drug Administration (FDA) official who will describe the process the agency used to develop a recommendation to transfer cannabis from Schedule I of the Controlled Substances Act (CSA) to Schedule III. Corey Burchman, a medical doctor from New Hampshire, has been a practicing physician for more than 30 years and “will testify as a medical expert in the practice of pain management, with significant clinical experience in the use of medical marijuana,” DEA said in the new filing. “Dr. Burchman will testify that he provided direct patient care for pain patients as an anesthesiologist and pain management physician following his residency and fellowship training in 1986 until 2019. He will testify that he was practicing at the Dartmouth-Hitchcock Medical Center in Hanover, NH when the medical center began prioritizing medical marijuana as a treatment modality for pain patients and he worked to transition many patients from treatment with opioids to treatment with marijuana. Dr. Burchman will further testify that in his medical opinion, medical marijuana provides a medical benefit to pain patients.” The New Hampshire doctor will also testify about “patient safety measures utilized in the industry regarding the cultivation, processing, and dispensing of medicinal marijuana, including caps on the monthly amount of medicinal marijuana allowed per patient along with product QR codes, certificates of analysis, and testing by certified labs,” given his experience with his state’s medical cannabis program. The other DEA witness is Dominic Chiapperino, who serves as director of the controlled substance staff with FDA’s Center for Drug Evaluation and Research. He will testify about federal health officials’ eight-factor analysis (8FA) analysis used to “assess marijuana’s currently accepted medical use (CAMU) in treatment in the United States,” the filing says. That includes an initial assessment from the Office of the Assistant Secretary for Health (OASH) that “found that licensed health care practitioners had widespread current experience with use of medical marijuana in jurisdictions where such medical use is recognized by entities that regulate the practice of medicine.” “Dr. Chiapperino will testify that he and the Controlled Substances Staff relied on OASH’s Part I assessment to complete FDA’s Part II review of marijuana’s CAMU. Dr. Chiapperino will testify to FDA’s assessment of the findings necessary to support placement in Schedule III, namely that marijuana has a potential for abuse less than the drugs or other substances in Schedules I and II, that marijuana has a CAMU for at least one therapeutic condition, and that abuse of marijuana may lead to moderate or low physical dependence or high psychological dependence.” A letter from FDA that DEA attached to the new filing said the health agency is allowing Chiapperino to testify “to the scientific and medical determinations that form the basis of the 8FA…, scientific and medical determinations underlying the evaluation performed in FDA’s assessment of CAMU…, and FDA’s recommendation to place marijuana in Schedule III.” “Dr. Chiapperino is not authorized to testify to matters outside of the aforementioned three topics, DEA said. Cannabis reform opponents have taken issue with the analysis federal health officials used to evaluate marijuana’s medical use as part of the rescheduling recommendation, which they say improperly departs from a prior test that had been used, and it is likely their attorneys will press the FDA staffer on the reasons for the change. DEA is technically the proponent of the proposed marijuana rescheduling rule and will fill the role of defending it during the hearing, for which no reform supporters were invited to testify. Some cannabis reform advocates have expressed skepticism that the agency will effectively argue for rescheduling given its long history of staunchly defending strict prohibition—but the new filing indicates that the government intends to highlight marijuana’s medical benefits during the hearing. It still remains to be seen, though, how the agency’s lawyers will cross-examine witness from the opposing parties and how its own witnesses will fare under questioning from opponents’ attorneys. Separately this week, marijuana reform opponents filed briefs previewing the arguments they plan to make in the rescheduling hearing—with briefs largely focusing on cannabis’s alleged health and safety harms. One of the groups, Smart Approaches to Marijuana, said it will call DEA pharmacologist Luli Akinfiresoye as a witness—a move that the agency has resisted in communications with the organization this week. The DEA official was previously an official witness for an earlier, subsequently cancelled hearing on marijuana rescheduling during the Biden administration. During that time, she submitted into the record a report that attempts to link cannabis consumption to psychosis, depression and impaired cognitive functioning. Meanwhile, Marijuana Moment this seek sent letters this week asking the DEA judge overseeing the proceedings and the DEA administrator to allow livestreaming of the hearing DEA Chief Administrative Law Judge Derek Julius last week issued a preliminary order laying out rules and timelines for the marijuana rescheduling proceedings—simultaneously recognizing that “national public interest in this issue predicates towards a policy of transparency” while also determining that “the hearing will not be televised, livestreamed, or broadcasted in any way.” As a result, people who wish to observe the historic cannabis reform process must attend in person in Arlington, Virginia under the judge’s order. In a letter sent to Julius on Tuesday, Marijuana Moment counsel Joseph A. Bondy noted that DEA permitted livestreaming of an earlier, subsequently cancelled hearing process on the proposal to reschedule cannabis that took place during the Biden administration. “That prior determination was correct. The public-interest rationale for contemporaneous access has not diminished,” Bondy wrote. “If DEA believes safety, witness-management, or operational concerns now require a more restrictive access regime, those concerns should be identified and addressed through narrow conditions rather than a categorical ban.” “In a proceeding of this public significance, and in light of DEA’s prior livestreaming directive, a public hearing is not meaningfully public if access depends on the happenstance of limited physical attendance,” Marijuana Moment’s attorney wrote to the DEA judge. “Delayed access to transcripts is no substitute for contemporaneous observation. The press reports events as they unfold. The public evaluates government action in real time. And in a proceeding of this magnitude, transparency is not a courtesy. It is a safeguard.” “For a substantial public audience seeking serious coverage of federal cannabis policy, Marijuana Moment is an important channel through which public understanding of this proceeding occurs.” — Marijuana Moment’s journalism is made possible by readers like you who value this work enough to support us with monthly pledges on Patreon. If you rely on our reporting to stay informed about key cannabis developments, please help us keep doing this by becoming a sustaining subscriber today. Backing us at the $25/month level also gets you access to our Bill Tracker so you won’t miss any important marijuana legislation in your state. — DEA last week announced that it had selected participants for the marijuana rescheduling hearing—and only opponents of the reform have been invited to take part, some of whom have filed litigation in an attempt to block the reform. No reform supporters who expressed intent to participate were invited. The hearing will begin on June 29 and is set to conclude no later than July 15. Acting Attorney General Todd Blanche in April issued an order that immediately reclassified state-licensed medical cannabis, as well as marijuana products approved by the Food and Drug Administration (FDA) from Schedule I of the Controlled Substances Act (CSA) to Schedule III. Under a separate order the acting attorney general signed, the upcoming hearing will consider more comprehensively moving marijuana to Schedule III. A prior hearing process on the marijuana rescheduling process that was initiated by the Biden administration stalled last year amid litigation over alleged improper communications and witness selection. The current marijuana rescheduling process is being challenged with several lawsuits that have been consolidated by a federal appeals court. Those pieces of litigation against the cannabis reform have been filed by state attorneys general, marijuana legalization opponents and a cannabis-focused biopharmaceutical corporation. Meanwhile, the already-enacted rescheduling of state-licensed medical cannabis is already having broad impacts. The Congressional Research Service published a report on the current cannabis rescheduling move explaining that certified patients who possess medical marijuana from state-licensed dispensaries now have certain protections under Schedule III. “The order appears to authorize end users to possess marijuana for medical use without a CSA-compliant prescription,” it says. The Bureau of Alcohol, Tobacco, Firearms and Explosives (ATF) has posted a draft update to a gun purchase form to acknowledge the federally legal status of medical marijuana under rescheduling. The revised section in question notably says that only “use or possession of marijuana for recreational purposes” is federally prohibited, leaving out the prior form’s mention of medical cannabis. The U.S. Department of the Treasury and Internal Revenue Service (IRS) said they plan to issue new tax guidance for the marijuana industry following rescheduling. The reform will benefit state-licensed marijuana businesses by allowing them to take federal tax deductions they’re currently barred from under an IRS code known as 280E that doesn’t apply to Schedule III substances. Even DEA, which has long opposed cannabis legalization and was accused of stalling the rescheduling process initiative by the Biden administration, has launched a registration process for state-legal marijuana businesses to take advantage of federal benefits that come with the reform. The Department of Transportation, on the other hand, issued guidance saying that use of state-legal medical cannabis is still no excuse for a positive drug test by truck drivers, pilots and other safety-sensitive workers. A congressional committee recently voted to block federal officials from taking further steps to carry out cannabis rescheduling. Read the government’s new filing in the marijuana rescheduling hearing below: The post DEA Will Highlight Testimony On Marijuana’s Medical Benefits In Rescheduling Hearing, New Filing Shows appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

Marijuana Moment has brought its request for public and media livestream access to the historic federal cannabis rescheduling hearings starting next week directly to the head of the Drug Enforcement Administration (DEA) after the judge overseeing the proceedings—which only involve opponents of the reform—said he wouldn’t consider filings from outside parties. A letter from Marijuana Moment counsel Joseph A. Bondy notes that “DEA has already determined that livestream access is appropriate here”—pointing out that the agency permitted streaming of an earlier, subsequently cancelled hearing process on the proposal to move cannabis from Schedule I of the Controlled Substances Act (CSA) to Schedule III that took place during the Biden administration. “The same public-interest rationale applies now,” he wrote to DEA administrator Terrance Cole on Thursday. Earlier this week, Marijuana Moment’s attorney had sent a letter to DEA Chief Administrative Law Judge Derek Julius, saying that “a public hearing is not meaningfully public if access depends on the happenstance of limited physical attendance.” The judge last week issued a preliminary order laying out rules and timelines for the marijuana rescheduling proceedings—simultaneously recognizing that “national public interest in this issue predicates towards a policy of transparency” while also determining that “the hearing will not be televised, livestreamed, or broadcasted in any way.” As a result, people who wish to observe the historic cannabis reform process must attend in person in Arlington, Virginia under the judge’s order. Julius later issued a separate order stating that any submissions to the tribunal from non-parties “lack standing and will not be considered”—and so Marijuana Moment is now taking the ask to Cole, the agency administrator. “DEA previously determined that livestreaming was the appropriate means of providing meaningful contemporaneous access in this same rulemaking, and DEA has not explained why the same public-interest and transparency considerations now warrant a materially more restrictive access regime,” Bondy wrote in the new letter. The agency announced on Thursday that it would make a transcript available at the conclusion of the multi-day hearing, but Marijuana Moment’s attorney wrote that it wouldn’t help the public follow the proceedings in real time on a daily basis. “A final transcript is useful, but it is not a substitute for livestream access. Livestreaming allows the public and press to observe the hearing as it unfolds, without vying for admittance, crowding the courtroom or affecting the proceeding,” the letter to Cole says. “Once a transcript is reviewed, corrected, and released several weeks after the testimony has been given, the opportunity for real-time observation, timely reporting, and informed public response has already passed.” “For a substantial public audience seeking serious coverage of federal cannabis policy, Marijuana Moment is an important channel through which public understanding of this proceeding occurs.” “To the extent DEA believes livestreaming is now inappropriate despite DEA’s prior directive in this rulemaking, Marijuana Moment respectfully requests a written explanation identifying the specific basis for that conclusion, including why the public-interest and transparency considerations that previously warranted livestreaming are outweighed here,” Bondy wrote. — Marijuana Moment’s journalism is made possible by readers like you who value this work enough to support us with monthly pledges on Patreon. If you rely on our reporting to stay informed about key cannabis developments, please help us keep doing this by becoming a sustaining subscriber today. Backing us at the $25/month level also gets you access to our Bill Tracker so you won’t miss any important marijuana legislation in your state. — Separately, medical cannabis advocates on Thursday sent a letter to Julius, the DEA judge who said he wouldn’t consider submissions from outside parties, also requesting livestream access. “Many patients with the greatest interest in this proceeding are unable to travel to Arlington, Virginia. Many are disabled, immunocompromised, elderly, financially constrained, or managing serious medical conditions,” the letter from Americans for Safe Access, Veterans Initiative-22, U.S. Pain Foundation, Realm of Caring, Montel Williams and other advocates says. “Even patients and advocates who can travel may not be physically able to wait in line for an uncertain chance at admission, only to be turned away once the limited seating is filled,” they wrote. “As such, the hearing may technically be open to the public, yet practically inaccessible to most.” Meanwhile, rescheduling opponents that are participating in the hearing filed statements this week previewing the anti-marijuana arguments they intend to make during the proceedings. The hearing will begin on June 29 and is set to conclude no later than July 15. Acting Attorney General Todd Blanche in April issued an order that immediately reclassified state-licensed medical cannabis, as well as marijuana products approved by the Food and Drug Administration (FDA) from Schedule I of the Controlled Substances Act (CSA) to Schedule III. Under a separate order the acting attorney general signed, the upcoming hearing will consider more comprehensively moving marijuana to Schedule III. A prior hearing process on the marijuana rescheduling process that was initiated by the Biden administration stalled last year amid litigation over alleged improper communications and witness selection. The current marijuana rescheduling process is being challenged with several lawsuits that have been consolidated by a federal appeals court. Those pieces of litigation against the cannabis reform have been filed by state attorneys general, marijuana legalization opponents and a cannabis-focused biopharmaceutical corporation. Meanwhile, the already-enacted rescheduling of state-licensed medical cannabis is already having broad impacts. The Congressional Research Service published a report on the current cannabis rescheduling move explaining that certified patients who possess medical marijuana from state-licensed dispensaries now have certain protections under Schedule III. “The order appears to authorize end users to possess marijuana for medical use without a CSA-compliant prescription,” it says. The Bureau of Alcohol, Tobacco, Firearms and Explosives (ATF) has posted a draft update to a gun purchase form to acknowledge the federally legal status of medical marijuana under rescheduling. The revised section in question notably says that only “use or possession of marijuana for recreational purposes” is federally prohibited, leaving out the prior form’s mention of medical cannabis. The U.S. Department of the Treasury and Internal Revenue Service (IRS) said they plan to issue new tax guidance for the marijuana industry following rescheduling. The reform will benefit state-licensed marijuana businesses by allowing them to take federal tax deductions they’re currently barred from under an IRS code known as 280E that doesn’t apply to Schedule III substances. Even DEA, which has long opposed cannabis legalization and was accused of stalling the rescheduling process initiative by the Biden administration, has launched a registration process for state-legal marijuana businesses to take advantage of federal benefits that come with the reform. The Department of Transportation, on the other hand, issued guidance saying that use of state-legal medical cannabis is still no excuse for a positive drug test by truck drivers, pilots and other safety-sensitive workers. A congressional committee recently voted to block federal officials from taking further steps to carry out cannabis rescheduling. Read the letter to the DEA administrator from Marijuana Moment’s attorney below: The post Marijuana Moment Takes Ask For Rescheduling Hearing Livestreaming Directly To DEA Head After Judge Says He Won’t Consider Request appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

Marijuana reform opponents have filed briefs previewing the arguments they plan to make in a hearing on the Trump administration’s move to reschedule cannabis that is set to start next week. Meanwhile, the Drug Enforcement Administration (DEA), which is formally the proponent of the reform to move marijuana from Schedule I of the Controlled Substances Act (CSA) to Schedule III has again made clear it will not be inviting supporters of rescheduling to participate. A brief from the states of Idaho, Indiana and Nebraska says that each of them “prohibits or severely restricts the availability of marijuana within its borders, as marijuana causes our citizens psychiatric harm and is linked to increases in homelessness, traffic accidents, illegal drug trafficking, and other crime.” The states said they intend to call Deepak Cyril D’Souz, the inaugural director of the Yale Center for the Science of Cannabis and Cannabinoids, as a witness in the hearing. “He is expected to testify regarding the abuse liability of cannabis, drawing upon evidence from controlled human laboratory studies, brain imaging, and epidemiologic research,” the statement says. “The available scientific evidence demonstrates that regular cannabis use can lead to cannabis use disorder in a substantial proportion of users.” It adds that he is “expected to summarize the scientific evidence regarding the principal public health risks associated with cannabis use, including: (1) an increased risk of serious mental illnesses, particularly psychotic disorders in susceptible individuals; (2) cannabis use disorder and addiction; (3) driving impairment; (4) adverse effects of cannabis exposure during adolescence and pregnancy on neurodevelopment; and (5) acute and chronic impairments in learning, memory, and other cognitive functions.” The states’ other witness will be Humboldt County, California Sheriff William Honsal, who will testify that “legalization and changes in marijuana laws contributed to a significant expansion of the illicit marijuana market rather than its elimination.” “Sheriff Honsal is expected to testify that the medical marijuana framework was frequently exploited by criminal enterprises,” the statement says. “Because healthcare providers issued ‘recommendations’ rather than prescriptions, there were no meaningful limits on dosage or quantity. He can testify that some recommendations authorized extraordinarily large quantities of marijuana. Some growers claimed authority to cultivate as many as 99 plants per patient and that individual plants could yield from one-quarter pound to as much as four pounds of marijuana. He will testify that there are cultivation sites capable of producing thousands of pounds of marijuana annually, particularly through indoor growing operations that can complete five or six harvest cycles each year.” “The Sheriff is expected to testify that, once marijuana ceased being categorically illegal, criminal organizations exploited perceived loopholes in the medical marijuana laws to mass-produce marijuana for interstate and international distribution,” the states said. Notably, Louisiana was initially a party in the rescheduling hearing along with the other states but was not mentioned in the latest brief. Separately, the Tennessee Bureau of Investigation (TBI), another party participating in the hearing, said its witness will be Erica Stephens, who serves as assistant special agent in charge of the Tennessee Dangerous Drugs Task Force. She will testify about “the impact marijuana has had on TBI’s mission of keeping Tennesseans safe and how deregulation of marijuana, including legalization of hemp, makes TBI’s enforcement efforts more difficult, encourages involvement of criminal organizations in the production and distribution of marijuana, and negatively impacts the health and safety of Tennesseans,” the agency’s filing said. Stephens will also testify about her view that the government’s marijuana rescheduling proposal is “deficient” and “overlooks or ignores substantial evidence relevant to the required eight-factor analysis that weighs strongly against rescheduling marijuana to Schedule III.” “Agent Stephens will testify that marijuana is being diverted from both federally approved and state-approved channels. Tennessee does not recognize any form of legal marijuana. This diversion takes place in two primary forms: (1) trafficking of illicit marijuana from states that license the cultivation, production, and distribution of marijuana, and (2) the growing of illegal marijuana in licensed hemp farms.” “Deregulation of marijuana presents a substantial public health risk. Agent Stephens will testify about how deregulation in states fosters a legal environment that can be exploited by criminal organizations,” the filing said. “Additionally, marijuana has a high association with crime and is the most associated with crimes against persons in Tennessee. Agent Stephens may also discuss evidence regarding traffic deaths caused by people driving under the influence of marijuana.” Meanwhile, Smart Approaches to Marijuana (SAM), a leading anti-legalization group that is participating in the proceedings, said it will call DEA pharmacologist Luli Akinfiresoye as a witness—a move that the agency has resisted in communications with the organization this week. The DEA official was previously an official witness for an earlier, subsequently cancelled hearing on marijuana rescheduling during the Biden administration. During that time, she submitted into the record a report that attempts to link cannabis consumption to psychosis, depression and impaired cognitive functioning. SAM said Akinfiresoye is “expected to testify that marijuana has a substantial potential for abuse, a well-documented capacity to produce dependence, and a broad range of adverse health consequences affecting multiple organ systems and vulnerable populations.” “She is also expected to testify that marijuana has clear dependence liability. She will explain that repeated THC exposure alters brain reward pathways, producing reinforcing effects that can lead to [Cannabis Use Disorder].” She is also “expected to testify that there are numerous adverse health consequences associated with marijuana use. Acute intoxication can impair memory, judgment, motor coordination, attention, and decision-making, increasing risks for accidents and impaired driving. Chronic use is associated with measurable alterations in brain structure and function, including changes in gray and white matter, reduced hippocampal volume, cognitive deficits, lower IQ, impaired memory, and diminished executive functioning. She will discuss these impacts as they relate to adolescent exposure, as marijuana may interfere with normal brain development and increase vulnerability to psychiatric disorders later in life.” The prohibitionist group is also hoping the Akinfiresoye will “testify that credible scientific research links marijuana use to serious mental health risks, including psychosis, schizophrenia, depression, anxiety, bipolar disorder exacerbation, and suicidality,” the prehearing statement said. Separately, SAM will also be calling former White House Office of National Drug Control Policy Director Bertha Madras, saying she will “testify that marijuana (1) has a high potential for abuse, (2) has no currently accepted medical use, and (3) lacks accepted safety for use under medical supervision, and thus does not meets the statutory standard for classification in any schedule other than Schedule I of the Controlled Substances Act.” Another participant, the National Drug & Alcohol Screening Association (NDASA), said it will call former Department of Transportation official Patrice Kelly as a witness. The statement goes on to describe testimony that the organization’s executive director, JoMcGuire, will provide, including how the government’s rescheduling proposal “failed to address the unintended safety impact” the reform “would have on transportation safety.” Meanwhile, DEA Administrator Terrance Cole rejected a request from the National Organization for the Reform of Marijuana Laws (NORML) to reconsider his decision not to invite the group as a participant in the hearing. Cole wrote that the group’s request “fails to sufficiently explain how or why NORML is adversely affected or aggrieved by the promulgation of a rule transferring marijuana….from schedule I to schedule III.” “You unambiguously state that ‘NORML supports removal from schedule I,’ and that ‘[s]chedule III may be better than schedule I.’ You further reiterate NORML’s position that transferring marijuana to schedule III only offers ‘partial relief,’ and that ‘complete relief’ requires that marijuana ‘be removed from the CSA schedules and regulated under a cannabis-specific federal framework better suited to cannabis, consumers, public health, state-law reality, and contemporary science.'” “While you contend that ‘NORML’s position is…directly adverse to the proposed rule’ because it wants marijuana removed from the CSA schedules entirely,” the DEA head said, “NORML has failed to demonstrate in either its participation request or its reconsideration request that it is adversely affected or aggrieved by the proposed rule, as opposed to the status quo of marijuana remaining in schedule I.'” Under a previous decision by the DEA administrator, only opponents of the reform are being invited to participate. Marijuana Moment this seek sent a latter asking the DEA judge overseeing the proceedings to reconsider his decision to prohibit livestreaming of the hearing. DEA Chief Administrative Law Judge Derek Julius last week issued a preliminary order laying out rules and timelines for the marijuana rescheduling proceedings—simultaneously recognizing that “national public interest in this issue predicates towards a policy of transparency” while also determining that “the hearing will not be televised, livestreamed, or broadcasted in any way.” As a result, people who wish to observe the historic cannabis reform process must attend in person in Arlington, Virginia under the judge’s order. In a letter sent to Julius on Tuesday, Marijuana Moment counsel Joseph A. Bondy noted that DEA permitted livestreaming of an earlier, subsequently cancelled hearing process on the proposal to move cannabis from Schedule I of the Controlled Substances Act (CSA) to Schedule III that took place during the Biden administration. “That prior determination was correct. The public-interest rationale for contemporaneous access has not diminished,” Bondy wrote. “If DEA believes safety, witness-management, or operational concerns now require a more restrictive access regime, those concerns should be identified and addressed through narrow conditions rather than a categorical ban.” “Limited physical seating in Arlington is not a meaningful substitute for livestreaming. Marijuana Moment, like many members of the press and public who follow federal cannabis policy nationally, cannot rely on a handful of available seats as a practical means of observing and reporting on the hearing. That is precisely why DEA’s prior livestreaming directive mattered: it allowed those physically outside the courtroom to observe the proceeding without disrupting the hearing, burdening security, or conferring party status on anyone.” “In a proceeding of this public significance, and in light of DEA’s prior livestreaming directive, a public hearing is not meaningfully public if access depends on the happenstance of limited physical attendance,” Marijuana Moment’s attorney wrote to the DEA judge. “Delayed access to transcripts is no substitute for contemporaneous observation. The press reports events as they unfold. The public evaluates government action in real time. And in a proceeding of this magnitude, transparency is not a courtesy. It is a safeguard.” “For a substantial public audience seeking serious coverage of federal cannabis policy, Marijuana Moment is an important channel through which public understanding of this proceeding occurs.” — Marijuana Moment’s journalism is made possible by readers like you who value this work enough to support us with monthly pledges on Patreon. If you rely on our reporting to stay informed about key cannabis developments, please help us keep doing this by becoming a sustaining subscriber today. Backing us at the $25/month level also gets you access to our Bill Tracker so you won’t miss any important marijuana legislation in your state. — DEA last week announced that it had selected participants for the marijuana rescheduling hearing—and only opponents of the reform have been invited to take part, some of whom have filed litigation in an attempt to block the reform. No reform supporters who expressed intent to participate were invited. The hearing will begin on June 29 and is set to conclude no later than July 15. Acting Attorney General Todd Blanche in April issued an order that immediately reclassified state-licensed medical cannabis, as well as marijuana products approved by the Food and Drug Administration (FDA) from Schedule I of the Controlled Substances Act (CSA) to Schedule III. Under a separate order the acting attorney general signed, the upcoming hearing will consider more comprehensively moving marijuana to Schedule III. A prior hearing process on the marijuana rescheduling process that was initiated by the Biden administration stalled last year amid litigation over alleged improper communications and witness selection. The current marijuana rescheduling process is being challenged with several lawsuits that have been consolidated by a federal appeals court. Those pieces of litigation against the cannabis reform have been filed by state attorneys general, marijuana legalization opponents and a cannabis-focused biopharmaceutical corporation. Meanwhile, the already-enacted rescheduling of state-licensed medical cannabis is already having broad impacts. The Congressional Research Service published a report on the current cannabis rescheduling move explaining that certified patients who possess medical marijuana from state-licensed dispensaries now have certain protections under Schedule III. “The order appears to authorize end users to possess marijuana for medical use without a CSA-compliant prescription,” it says. The Bureau of Alcohol, Tobacco, Firearms and Explosives (ATF) has posted a draft update to a gun purchase form to acknowledge the federally legal status of medical marijuana under rescheduling. The revised section in question notably says that only “use or possession of marijuana for recreational purposes” is federally prohibited, leaving out the prior form’s mention of medical cannabis. The U.S. Department of the Treasury and Internal Revenue Service (IRS) said they plan to issue new tax guidance for the marijuana industry following rescheduling. The reform will benefit state-licensed marijuana businesses by allowing them to take federal tax deductions they’re currently barred from under an IRS code known as 280E that doesn’t apply to Schedule III substances. Even DEA, which has long opposed cannabis legalization and was accused of stalling the rescheduling process initiative by the Biden administration, has launched a registration process for state-legal marijuana businesses to take advantage of federal benefits that come with the reform. The Department of Transportation, on the other hand, issued guidance saying that use of state-legal medical cannabis is still no excuse for a positive drug test by truck drivers, pilots and other safety-sensitive workers. A congressional committee recently voted to block federal officials from taking further steps to carry out cannabis rescheduling. Read the new documents in the marijuana rescheduling hearing below: The post Marijuana Opponents Preview Arguments For Next Week’s Rescheduling Hearing In New Filings appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

Butuh teks kosong untuk keperluan copy-paste di media sosial, aplikasi perpesanan, atau pengujian sistem? Anda berada di tempat yang tepat. Layanan kami menyediakan karakter khusus yang tidak terlihat oleh mata manusia namun terbaca oleh sistem sebagai teks, memungkinkan Anda untuk mengirim pesan kosong, membuat nama profil yang tidak terlihat, atau memformat kolom input sesuai kebutuhan Anda.

DEA defends HHC ban; NH lawmakers on overriding marijuana greenhouse veto; MA push to save legalization; VA advocates press gov on cannabis penalties Subscribe to receive Marijuana Moment’s newsletter in your inbox every weekday morning. It’s the best way to make sure you know which cannabis stories are shaping the day. Get our daily newsletter. Email address: Leave this field empty if you're human: Your support makes Marijuana Moment possible… Your good deed for the day: donate to an independent publisher like Marijuana Moment and ensure that as many voters as possible have access to the most in-depth cannabis reporting out there. Support our work at https://www.patreon.com/marijuanamoment / TOP THINGS TO KNOW Bipartisan groups of Senate and House members filed a marijuana banking bill that’s intended to ease the cannabis industry’s access to financial services. The Drug Enforcement Administration filed briefs in response to lawsuits that claim the agency is improperly classifying the cannabinoid hexahydrocannabinol (HHC) as an illegal Schedule I substance and not as federally legal hemp—in defiance of Congress. New Hampshire lawmakers are preparing a push to override Gov. Kelly Ayotte’s (R) veto of a bill to allow medical cannabis companies to cultivate in greenhouses, which they say would make marijuana more affordable and accessible for patients. A coalition of Massachusetts marijuana business leaders, healthcare professionals and other advocates launched a campaign to defeat an initiative to roll back that state’s cannabis legalization law that is expected to appear on the November ballot. Marijuana reform advocates are pressing Virginia Gov. Abigail Spanberger (D) to remove budget provisions that would dramatically increase penalties for public cannabis use—citing new data that shows enforcement is carried out on a racially disproportionate basis. / FEDERAL The Senate Caucus on International Narcotics Control held a hearing on “the risks posed by Mexican drug cartels to U.S. national security.” Rep. James Comer (R-KY) tweeted, “President Trump is standing with Kentucky’s hemp farmers and the hardworking Americans in this industry. This administration is right: Congress must pass a responsible regulatory framework that provides certainty for hemp farmers and protects quality American jobs.” Nebraska independent U.S. Senate candidate Dan Osborn tweeted, “People who consume marijuana should be able to purchase and possess firearms. This is common sense.” / STATES New Mexico Gov. Michelle Lujan Grisham (D) is calling for a criminal investigation into the Drug Enforcement Administration following reports that the agency allowed hundreds of thousands of fentanyl pills to reach the streets while pursuing larger trafficking cases. California Gov. Gavin Newsom (D) announced the awarding of $227 million grant funding to support local efforts addressing the public health and safety impacts of cannabis legalization. Wisconsin gubernatorial candidates discussed marijuana reform at a forum. The Texas Senate Health and Human Services Committee will hold a hearing on the “societal impacts of THC product consumption” on Tuesday. A Pennsylvania representative discussed her legislation to restrict hemp THC products. Illinois regulators published guidance about recently enacted cannabis reform legislation. New York officials launched a new Center of Excellence for Cannabis Care and Health Equity. — Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments. Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. — / LOCAL The Sacramento, California City Council approved a proposal to create a five-year pilot program allowing on-site consumption lounges at licensed marijuana dispensaries. / INTERNATIONAL Ireland’s minister of state at the Department of Health said the government has no plans to decriminalize all drugs in line with a legislative committee’s recommendation. / SCIENCE & HEALTH A study found that “after adult-use legalization and commercialization, doctor-recommended use decreased by more than half among past-month cannabis users, even as overall use remained stable,” suggesting that “legalization and commercialization in California may have altered patterns of medical utilization without reducing population-level use.” A study of mice with an Angelman syndrome model found that “cannabidiol corrects sleep deficits and reduces spontaneous seizures.” / ADVOCACY, OPINION & ANALYSIS Americans for Safe Access, Veterans Initiative-22, U.S. Pain Foundation, Realm of Caring, Montel Williams and other advocates sent a letter asking a Drug Enforcement Administration judge to reverse his decision to not allow livestreaming of the cannabis rescheduling hearing set to begin next week—following a similar request made earlier this week by Marijuana Moment. / BUSINESS Glass House Brands Inc. has been approved to list its shares on the New York Stock Exchange. Ascend Wellness workers in Barry, Illinois went on strike. Kansas City Cannabis Company is being sued for allegedly deceiving customers with hidden fees through the use of cashless ATMs. Make sure to subscribe to get Marijuana Moment’s daily dispatch in your inbox. Get our daily newsletter. Email address: Leave this field empty if you're human: The post Cannabis banking legislation filed in Congress (Newsletter: June 26, 2026) appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

The Drug Enforcement Administration (DEA) is resisting two hemp companies’ efforts to challenge its determination that a cannabinoid produced synthetically from components of the cannabis plant is federally illegal. DEA issued a rule last month saying that while it had already considered hexahydrocannabinol (HHC) to be a Schedule I illegal substance under the federal Controlled Substances Act (CSA), the agency will now giving the compound its own unique drug code for classification. That move is being contested in separate lawsuits from hemp businesses that say the agency’s decision is “unlawful.” In addition to filing petitions for review, the companies are also asking federal courts to issue a stay blocking the agency’s action while the lawsuits proceed. DEA, in briefs filed in the cases this week, argued that each petitioner “fails to meet any of the factors required to show that a stay pending review would be warranted.” “The rule does not affect HHC’s previous status as a schedule I substance—all it does is separately list HHC and give it a separate drug code,” the agency’s briefs said. “With or without the final rule, HHC is a schedule I controlled substance. Thus, even if this Court were to stay the final rule pending review, [the companies] would remain subject to the same preexisting legal and commercial risks for its actions related to HHC,” they say, “In contrast, a stay would undermine the government’s efforts to improve the regulation of HHC, including any approval process for applications to manufacture or procure HHC in limited quantities for permitted purposes. The public interest likewise disfavors a stay, which would create confusion about HHC’s status as a schedule I controlled substance.” HHC can be found in trace amounts in cannabis plants but is also synthesized by hydrogenating cannabidiol (CBD). It’s sometimes sprayed on cannabis flowers that are low in delta-9 THC, the most well-known psychoactive component of marijuana, and its psychoactive effects are reportedly similar. While the 2018 Farm Bill federally legalized hemp and its derivatives with less than .3 percent delta-9 THC on a dry-weight basis, DEA says that only applies to naturally occurring, and not synthetic, cannabinoids. As such, it is the agency’s position that HHC does not fall under the definition of legal hemp. One of the ongoing cases, filed by Bluestar Operations, LLC before the U.S. Court of Appeals for the Fourth Circuit, cites a prior ruling in that jurisdiction that found the hemp-derived cannabinoid THC-O-acetate is federally legal despite DEA’s claim to the contrary. “Congress intentionally employed expansive statutory language and did not prohibit cannabinoids subjected to ordinary extraction, refinement, conversion, hydrogenation, distillation, or similar manufacturing processes commonly utilized throughout the hemp industry,” the complaint says. DEA’s move “conflicts with the plain text, structure, and purpose of the 2018 Farm Bill and unlawfully inserts limitations Congress neither intended, nor enacted,” it says. The agency’s action has “already caused immediate and concrete harm to the Petitioner, including substantial compliance costs, business uncertainty, reputational harm, disruption of commercial relationships, and interference with ongoing operations.” “Congress, not executive agencies like the DEA, defines the scope of federal criminal liability. The DEA lacks authority to narrow Congress’s legalization of hemp cannabinoids through interpretive construction unsupported by statutory text.” Bluestar said in a new response to DEA’s initial reply brief that the agency is “unable to defend the merits of treating hemp-derived HHC as a Schedule I controlled substance—a position contrary to binding Circuit precedent which this Court rejected” in the prior case on ThC-O-acetate. “Respondents recast the challenged DEA rule as a weightless ‘technical amendment’ that injures no one and decides nothing,” it said. “They then flip the script by arguing that Bluestar lacks standing to challenge it. Respondents cannot have it both ways.” The other new suit was brought by IHC Investments, Inc. in the U.S. Court of Appeals for the Ninth Circuit, which previously ruled that the federal legalization of hemp through the 2018 Farm Bill removed restrictions on a wide range of molecules produced by the cannabis plant—including the psychoactive cannabinoid delta-8 THC. The petition says that “DEA effectively, and thus unlawfully, attempts to expand federal criminal liability through administrative interpretation, unsupported by the plain statutory text of the enabling legislation.” “Congress did not prohibit converted cannabinoids, hydrogenated cannabinoids, or cannabinoids subjected to ordinary commercial processing techniques,” the complaint says. “Congress did not clearly authorize the DEA to criminalize broad categories of hemp-derived cannabinoids through administrative interpretation.” Both petitions argue that DEA’s move last month violates the major questions doctrine, a precedent holding that if an agency seeks to decide an issue of major national significance, that action needs to be supported by clear congressional authorization. The agency’s ban of HHC “carries enormous economic and political significance affecting a nationwide hemp industry involving billions of dollars in commerce,” the litigation brought by Bluestar says. David Sergi, the attorney leading the new Ninth Circuit case for IHC Investments, said in a press release on Thursday that DEA’s action “directly conflicts” with the 2018 Farm Bill the federally legalized hemp and its derivatives. “The DEA’s ruling has already caused immediate and concrete harm to hemp businesses nationwide,” he said. “That the reclassification has led to the immediate cancellation of contracts, loss of banking relationships, and the potential destruction of significant inventory.” DEA, for its part, said in the rule it filed last month that “only tetrahydrocannabinols in or derived from the cannabis plant—not synthetic tetrahydrocannabinols—are excluded from control as ‘tetrahydrocannabinols in hemp.'” “To clarify further, tetrahydrocannabinols produced through chemical conversion, even when hemp derived are considered synthetically produced for purposes of the CSA, do not qualify as ‘tetrahydrocannabinols in hemp’ under” the 2018 Farm Bill, the agency said. The Federal Register notice wasn’t the first time that DEA addressed the legal status of HHC. In a 2023 letter, Terrance Boos, chief of DEA’s Drug and Chemical Evaluation Section, wrote that HHC “does not occur naturally in the cannabis plant and can only be obtained synthetically, and therefore does not fall under the definition of hemp.” The new filing signed by DEA Administrator Terrance Cole said that “this rule does not affect the continuing status of hexahydrocannabinol as a schedule I controlled substance in any way.” “This action, as an administrative matter, establishes a separate, specific listing for hexahydrocannabinol in schedule I of the CSA and assigns a DEA drug code for this substance,” it said. “This action will allow DEA to establish an aggregate production quota and grant individual manufacturing and procurement quotas to DEA-registered manufacturers of hexahydrocannabinol, who had previously been granted individual quotas for such purposes under the drug code for tetrahydrocannabinols.” The DEA notice cited a move last year by an international drug control body to add HHC to Schedule II of the United Nations Convention on Psychotropic Substances of 1971—but the document doesn’t note that when the Commission on Narcotic Drugs (CND) took the action, the U.S. was the only country to abstain from the vote. DEA said that the U.S. Department of Health and Human Services (HHS) “concurs with the direct listing and drug code assignment of hexahydrocannabinol in the CSA.” Meanwhile, under provisions of a large-scale spending bill signed by President Donald Trump late last year, the federal definition of legal hemp is set to change in November. Unless that language is altered or its effective date is delayed, as some lawmakers are pushing for, only hemp products with up to 0.4 milligrams of total THC per container will remain legal after November 12. At the same time, however, the Trump administration is moving to more broadly reschedule marijuana under federal law, with a DEA hearing on the issue set to begin next week. Read recent filings in the cases below: Photo courtesy of Mike Latimer. The post DEA Defends Stance That Synthetic Cannabis Compound HHC Is Federally Banned In Response To Industry Lawsuits appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

A coalition of Massachusetts marijuana business leaders, healthcare professionals and other advocates have launched a campaign to defeat an initiative to roll back that state’s cannabis legalization law that is expected to appear on the November ballot. The Stop the Repeal Campaign held a press conference on Thursday to announce the effort to urge voters to reject the proposal, which would repeal laws allowing the regulated commercial sales of recreational marijuana while maintaining legal possession and continuing the medical cannabis system. “Repealing recreational cannabis laws in Massachusetts will not only take us backwards—it will negatively impact our communities that are already struggling with budget shortfalls and locally owned small businesses that have invested their life savings into building their legal businesses that create jobs and support local economies,” Ryan Dominguez, chair of the campaign said. “Since legalization, the cannabis industry has brought in close to $2 billion in state and local revenue, generating hundreds of millions of dollars annually in support of public health, public safety, and many other wide-reaching community investments,” he said. “We look forward to standing alongside our allies as we educate voters on what this ballot initiative actually does and fight back against out-of-state special interest groups pushing this regressive policy.” Fitchburg Mayor Sam Squailia also spoke at Thursday’s press conference. “At a time when state and local governments are already facing significant budget pressures, repealing recreational cannabis laws would be a costly mistake,” she said in support of the campaign. “Legal cannabis generates critical revenue that communities like Fitchburg rely on to fund our schools, improve transportation, and support essential services. “Recriminalizing adult-use cannabis would not only turn back the clock on sensible policy, it would blow a hole in state and municipal budgets at a moment when we simply cannot afford it,” Squailia said. “Our residents deserve investments in our communities, not cuts to the programs they depend on every day.” The campaign has highlighted the fact that Massachusetts has generated more than $2 billion in tax revenue from legal marijuana sales and has over 700 licensed business that support at least 20,000 jobs in the state. A safe, regulated, and legal cannabis industry is vital for Massachusetts. Tomorrow, a powerful coalition, including public health experts, doctors, and local mayors, will be gathering to make their voices heard and protect the progress we've made. https://t.co/IRu1HVawBo pic.twitter.com/gtNchPXQoV — Marijuana Policy Project (@MarijuanaPolicy) June 24, 2026 Earlier this month, the campaign behind the legalization rollback measure, the Coalition for a Healthy Massachusetts, fired a signature gatherer it says was shown appearing to engage in “wholly unacceptable” conduct in a recent video. As Marijuana Moment reported, a man petitioning for the Massachusetts initiative as well as a similar anti-cannabis proposal in Maine was depicted in recent social media posts seeming to argue that voters who support legal marijuana access should sign the petitions in order to advance or protect reform. The campaign later said it has “zero tolerance for any circulation tactics that would mislead petition signers.” “The identified canvasser was immediately terminated, in coordination with our vendor, upon being made aware of the alleged conduct,” the group said. “The conduct apparent in the video would be wholly unacceptable and does not reflect how this campaign operates. We demand honesty, transparency and professionalism from everyone associated with our effort.” A video posted to Reddit of the signature gatherer shows the man collecting signatures outside a retail store in Massachusetts next to a sign that says “keep cannabis legal.” When confronted by a marijuana reform supporter who recorded the petitioner’s interactions with voters, he appeared to be trying to convince them that it is important to qualify the anti-cannabis measure for the ballot in order to then defeat it. “This is what we’re fighting against right here. That’s why we vote no,” he said. “If we can get this to the ballot right here, we vote no.” The person who captured the video pointed out that Massachusetts voters already approved marijuana legalization years ago, and that the only way it could be imminently repealed is if the new ballot measure qualified for the November election. If the initiative does not get enough signatures to go before voters, the state’s laws will remain the same. “It’s my job,” the petitioner insisted, however. “I know what I’m talking about.” “It’s a group of rich folks from out of state that want to basically take marijuana to when it was a medical marijuana card,” he said. “We don’t want that to happen.” The same man also appeared to also be gathering signatures for a separate measure in Maine that would similarly repeal laws allowing regulated adult-use marijuana sales and home cultivation rights for adults while keeping possession legal and adding new testing requirements for medical cannabis. A staffer for the prohibitionist organization Smart Approaches to Marijuana (SAM), whose affiliated group SAM Action is largely funding the anti-cannabis ballot campaigns in both states, declined to comment about the petitioner’s conduct when reached by Marijuana Moment. The campaigns have previously been accused of misleading petitioning tactics. In Massachusetts, some voters reported that the campaign used fake cover letters for other ballot measures on unrelated issues like affordable housing and same-day voter registration. Legal cannabis supporters filed a formal complaint about the prohibitionist effort’s tactics, but the State Ballot Law Commission rejected the challenge. Under state law, Massachusetts ballot campaigns must turn in signatures in two waves. After the first submission, the legislature gets a chance to enact proposed ballot measures after organizers submit an initial round of petitions. Lawmakers last month declined to act on the anti-marijuana measure, however, and now organizers need to submit additional 12,429 certified signatures by July 1 to make the November ballot. The measure faced a legal challenge from cannabis industry operatives who argued it contains “impermissibly unrelated subjects,” and that the state attorney general’s official summary is “misleading and deficient.” The state Supreme Judicial Court heard oral arguments on the litigation challenging the anti-marijuana initiative but it ultimately ruled against the challenge. Photo courtesy of Mike Latimer. The post Massachusetts Advocates Launch Campaign To Defeat Marijuana Legalization Rollback Ballot Initiative appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

A bipartisan coalition of U.S. senators have filed a bill to protect banks from being punished for providing financial services to marijuana businesses. The Secure and Fair Enforcement Banking (SAFE) Act is intended to ease the cannabis industry’s access to financial services, which have been difficult to obtain for some businesses in the sector under ongoing federal prohibition. Led by Sen. Jeff Merkley (D-OR) and cosponsored by Sens. Lisa Murkowski (R-AK), Elizabeth Warren (D-MA) and Steve Daines (R-MT), the newly refiled measure comes days ahead of the start of a hearing on the Trump administration’s move to reschedule marijuana under federal law. Earlier iterations of the banking legislation have been introduced in past sessions of Congress, and while versions have been approved by the House of Representatives on several occasions, the reform has never been enacted into law. The Senate Banking Committee approved a cannabis banking measure in 2023 but it was not subsequently taken up on the floor and died at the end of the 118th Congress. — Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments. Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. — Sen. Tim Scott (R-SC), who currently chairs the banking panel, said last month that the fact that marijuana remains illegal at the federal level while more states legalize it has created a “quandary” for cannabis businesses and banks that wish to serve them. Even though Scott has opposed the cannabis banking reform in the past, he said that the bill would “allow for the banking question to be solved by making it legal to bank it,” Scott said. “What you don’t want is to have a situation where you have these cash rooms where you have hundreds of thousands of dollars cash sitting in a location. Everyone knows you can’t bank it and therefore the criminal activity is much higher in these places.” Beyond banking access for businesses, the new bill, S.4942, also contains provisions to ensure that marijuana industry workers can get access to federally backed mortgage loans. Read the full the cannabis banking bill below: The post Bipartisan Senators File Marijuana Banking Bill As Trump’s Rescheduling Move Advances appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

New Hampshire lawmakers and advocates are pushing to override the governor’s veto of a bill to let medical cannabis companies grow marijuana in greenhouses. Supporters say the proposal will make cannabis more affordable and available for patients, and it passed the Senate and House of Representatives in voice votes this session—but Gov. Kelly Ayotte (R) vetoed it this month. “I do not support expanding the cultivation of marijuana in our state,” the governor said. But now, bipartisan lawmakers are pushing back, with some saying they plan to vote to override the governor’s action. “I disagree with the governor’s decision to veto SB 468,” Sen. Howard Pearl (R), the lead sponsor of the legislation, told Marijuana Moment. “This bipartisan bill would have provided a practical way to lower costs for patients with serious medical conditions while maintaining the rigorous oversight and safeguards that have made New Hampshire’s Therapeutic Cannabis Program successful.” “At a time when affordability remains a significant challenge for many families, we should be looking for responsible ways to expand access to treatment and ease financial burdens,” he said. Sen. Tara Reardon (D) similarly said she is “disappointed” in the governor’s action, which she said will result in “denying cost-saving measures for more than 17,000 veterans and patients across New Hampshire who rely on medical cannabis as an important component of their physician-recommended care.” “I hope my Senate colleagues will join me in voting to override the veto and pass the bill into law,” she told Marijuana Moment. The two lawmakers also recently authored an op-ed together in The Concord Monitor, arguing that New Hampshire’s medical cannabis program “is at a disadvantage compared to neighboring states, all of which allow greenhouse cultivation and benefit from lower prices.” The legislation says that “each alternative treatment center registered under this section may request authorization to operate a greenhouse cultivation location, at the same or at a different location than its existing cultivation location, in order to reduce energy costs and provide lower prices for registered qualifying patients.” The only person to testify against the bill this session was a former state lawmaker who now serves as chair of the prohibitionist organization Smart Approaches to Marijuana NH. — Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments. Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. — Ayotte has separately threatened to veto any marijuana legalization bill that reaches her desk. The governor said last year that her position on the reform would not change even as the federal government moved forward with rescheduling the plant. “I understand that the governor doesn’t support legalization, but vetoing a few secure greenhouses? It’s hard to understand how this is even controversial,” Matt Simon, Matt Simon, director of public and government relations at the medical marijuana provider GraniteLeaf Cannabis, told Marijuana Moment. “Our team is just trying to improve efficiency so we can make therapeutic cannabis more affordable for patients.” (Disclosure: Simon supports Marijuana Moment’s work via a monthly pledge on Patreon.) In 2024, then-Gov. Chris Sununu (R) vetoed a similar proposal to allow cannabis businesses to cultivate in greenhouses. The House had enough votes to override that action, but the Senate did not. Photo courtesy of Chris Wallis // Side Pocket Images. The post New Hampshire Lawmakers Push To Override Governor’s Veto Of Medical Marijuana Greenhouse Cultivation Bill appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

Welcome to Aerocity's most exclusive adult entertainment destination, where every encounter is crafted to exceed your wildest expectations. Our Escort Aerocity service offers a diverse selection of stunning companions who are masters in the art of pleasure. Each girl is carefully selected, verified, and trained to provide an experience that goes beyond the ordinary. Whether you need a dinner date, a travel companion, or a private evening of passion, our companions are ready to fulfill your every desire. With competitive pricing and complete discretion, we make luxury accessible to everyone. Call now and make your fantasy a reality in Aerocity.

Welcome to CTNYT, your trusted destination for premium companionship services in Jaipur. We are dedicated to connecting clients with elegant, sophisticated, and discreet companions who value professionalism, privacy, and respect. Our platform focuses on providing a seamless experience with verified profiles, personalized assistance, and complete confidentiality. Whether you are visiting Jaipur for business, leisure, social events, or simply seeking quality companionship, CTNYT offers a carefully curated selection of companions to suit different preferences. Our commitment to discretion, reliability, and customer satisfaction has helped us build a reputation as a trusted platform in the industry. If you are searching for High profile escorts in Jaipur, CTNYT strives to provide a premium and professional experience while maintaining the highest standards of privacy and client care.

As Virginia’s governor weighs changes to budget legislation that lawmakers approved this week, marijuana reform advocates are urging her to cancel out a section that would dramatically increase penalties for public consumption of cannabis—which they say will be enforced in a racially discriminatory manner based on new data they have obtained. The budget bill passed by the legislature contains provisions that advocates generally support to legalize recreational marijuana sales—but it would also increase the current $25 fine for using cannabis in a public place by 900 percent to $250—a spike that advocates are calling a “poverty penalty.” A coalition of advocacy groups led by Marijuana Justice on Wednesday released new enforcement stats that they obtained through the Virginia Freedom of Information Act (FOIA) that they say “proves that legalization has not ended racially biased marijuana policing” in the state. The advocates gave the data to Christopher Newport University’s Center for Crime, Equity and Justice Research and Policy, which conducted an analysis. The state information shows that since noncommercial cannabis legalization took effect in Virginia in 2021, 185 white people and 179 Black people have been charged with public consumption. “When analyzing these totals against the overall racial breakdown in Virginia, it is clear that Black individuals are disproportionately more likely to be charged for public consumption of marijuana than white individuals,” the university center said. “Specifically, Black individuals are approximately 3.29 times more likely to be charged than white individuals.” “If representation were perfectly proportional to the state’s population, the expected breakdown would be approximately 255 white individuals and 75 Black individuals,” the analysis said. Gov. Abigail Spanberger (D) has already said she will be using her authority to send back proposed amendments for lawmakers to consider ahead of a July 1 budget deadline. That likely includes technical fixes to the marijuana sections, such as removing question marks that were left in the legislation as passed—but advocates also want her to make the substantive change of rescinding the public use fine increase. Chelsea Higgs Wise, executive director of Marijuana Justice, said that the state’s previously enacted law legalizing cannabis possession “was meant to stop the disproportionate targeting of Black communities, yet the state’s own FOIA data tells a different story.” The penalty increase under the approved legislation will not take effect until July 1 of next year, raising the possibility that lawmakers could pass legislation next session to rescind it. But “postponing harm is not the same as preventing it, and we reject it outright,” Wise told Marijuana Moment. “Delaying a 900 percent fine increase until 2027 does not change its impact. This remains a poverty penalty. Address this now, not later.” “With the data in hand, Governor Spanberger should do the right thing and be an advocate for Black community members by striking the increase from the budget,” she said. Marijuana Justice and other groups like the ACLU of Virginia, National Organization for the Reform of Marijuana Laws, Marijuana Policy Project, Drug Policy Alliance and Latino Cannabis Alliance, among others, recently sent a letter urging lawmakers and the governor not to boost the cannabis penalty, saying it would “deepen racial and economic disparities.” “Higher fines and penalties for low-level marijuana offenses are not neutral,” the organizations wrote in a letter to Spanberger and legislators. “They are enforced disproportionately against Black and brown communities, create debt that low-income people cannot afford and can trigger cascading harms in immigration, housing, education and employment.” “Virginia should not recreate over-policing and over-incarceration through fines and fees when the stated goal of legalization is public health, equity, repair and reducing criminalization,” they said. The new letter, which was also signed by Parabola Center for Law and Policy, Nolef Turns Inc., Justice Forward Virginia, New Virginia Majority and Virginia NORML, along with other groups, calls on state officials to: Maintain the $25 civil fine for public consumption. Reject any proposals that raise fines or add criminal penalties for low-level marijuana use. Center racial equity and harm reduction in all cannabis policies. Ensure legalization reduces over-policing and over-incarceration instead of recreating them through fines and fees. Ensure policy is based on data rather than creating punitive policy first and looking for justification later. “These steps will help Virginia move toward real legalization that repairs past harms, prioritizes public health, protects vulnerable communities and keeps people out of the criminal legal system,” the letter says. “They also align with concerns raised by legislative leaders that expanding criminal penalties would repeat the very harm legalization was intended to address.” Drug Policy Alliance separately launched an online action alert that Virginia residents can use to send messages urging the governor and lawmakers to pull back the proposed cannabis penalty increase. Spanberger last month vetoed a previous measure to legalize recreational cannabis sales after lawmakers rejected her proposed amendments to the plan. She later negotiated with Sen. Lashrecse Aird (D) and Del. Paul Krizek (D), who sponsored the earlier measure, on a compromise deal that was included in the budget legislation that passed this week. The new plan differs significantly in several ways from the earlier legislation. For example, it sets the launch date for recreational marijuana sales at July 1, 2027, which is what Spanberger proposed in contrast to the January 1 date in what lawmakers had passed. It also sets the legal public marijuana possession and per-transaction purchase limit at 2 ounces, an increase from the current legal limit of one ounce. The legislation lawmakers passed earlier this year would have allowed adults to possess up to 2.5 ounces. The bill also cedes to Spanberger on language to increase a marijuana excise tax from 6 percent to 8 percent after two years of legal sales. By way of compromise, the new agreement would make public consumption of marijuana punishable by a civil penalty of $250—a significant increase from the $25 in current law but less harsh than the class 4 criminal misdemeanor the governor sought in her proposed changes to the previous bill. Lawmakers passed the initial cannabis sales bills in March, but the governor then suggested changes to the legalization proposal—including delaying the start date for sales by six months, increasing taxes and instituting new criminal penalties for cannabis consumers. The legislature in April declined to take up the amendments during a one-day reconvened session, however, effectively rejecting them. Spanberger then issued a veto. Spanberger said this month that she was having “really productive” and “incredible” conversations with lawmakers about crafting a compromise approach to legalizing adult-use cannabis sales, and Marijuana Moment previously reported on the ongoing talks. The governor, meanwhile, has tried to publicly explain her veto—including by saying it is her view that “taking a little bit longer” to launch the market is not something she sees as “negative” because it is more important to get the details right than to do it fast. A recent survey found that bipartisan majorities of Virginia voters wanted Spanberger to sign the cannabis legislation into law, and that they specifically disagreed with her desire to slow the launch timeline for legal sales. The governor recently acknowledged in a separate interview that “a lot of people are not pleased” with her veto of the cannabis legislation. “Friends and family are displeased as well,” she said. Spanberger has repeatedly responded to criticism of her cannabis amendments from the bill sponsors and advocates by saying the suggested changes came after she spoke to the leaders of other states that have already implemented adult-use marijuana markets. A spokesperson for Spanberger declined to name any other governors she talked to about cannabis in response to a question from Marijuana Moment, however. The governor separately sought to explain her veto in an earlier interview, reiterating that she supports launching a legal cannabis market but worried about what she called a “rushed timeline” and “far more stores across Virginia” than she thinks are appropriate. Personal marijuana possession and home cultivation of marijuana has been legal in Virginia since 2021, but then-Gov. Glenn Youngkin (R) twice vetoed bills to provide consumers with a way to legally purchase regulated adult-use cannabis. Here are the key details of the new cannabis plan in the budget and how it compares to legislation that Spanberger vetoed—SB 542 and HB 642—as well as her previously proposed amendments to those measures: Adults would be able to purchase up to 2 ounces of marijuana in a single transaction, or up to an equivalent amount of other cannabis products as determined by regulators. That would represent an increase from the limit in current law of 1 ounce. Lawmakers previously proposed setting the amount at 2.5 ounces and the governor only wanted 2 ounces. Legal sales could begin on July 1, 2027. Lawmakers previously set the date for January 1, 2027, but the governor wanted it pushed back to July 1. There would be an excise tax of 6 percent on cannabis sales as well as a 5.3 percent retail sales and use tax, and municipalities would be allowed to set an additional local tax of up to 3.5 percent. Starting on July 1, 2029, the state excise tax would increase to 8 percent, in line with the governor’s previously proposed amendments. Revenue would be distributed to the Cannabis Equity Reinvestment Fund, early childhood education, the Department of Behavioral & Developmental Health Services and public health initiatives. The earlier measure passed by lawmakers would have allocated specific percentages to each, but the new language doesn’t specify what portion of revenue will go to each program. The governor, in her amendments, wanted to put all revenue into the general fund while earmarking it “for purposes such as early childhood education, behavioral health, public health awareness, prevention, treatment, and recovery services, workforce development, reentry, indigent criminal defense, and targeted reinvestment in historically disadvantaged communities.” Her amendment also sought to eliminate support for the Cannabis Equity Reinvestment Fund. The Virginia Cannabis Control Authority would oversee licensing and regulation of the new industry, and will also take on oversight of hemp, which is currently under the Department of Agriculture and Consumer Services. The body would be governed by a five-member board of directors appointed by the governor, whereas the bill previously passed by lawmakers contemplated a seven-member body with four appointed by the governor, two appointed by the speaker of the House and one appointed by the Senate Rules Committee. The definition of what constitutes a legal hemp product would be narrowed by removing a provision from current law that allows those containing more than 2 milligrams of total THC per package if they also have a ratio of CBD to THC that is 25:1 or more. Up to 350 retail marijuana stores would be allowed to be licensed to operate across the state, the same number that lawmakers had approved and greater than the 200 the governor had proposed. Local governments would not be able to opt of allowing marijuana businesses to operate in their area. Delivery services would be allowed. Serving sizes would be capped at 10 milligrams THC, with no more than 100 mg THC per package. Public use of marijuana would be a civil violation punishable by a $250 fine. That is ten times more than the $25 fine under current law, but less harsh than the class 4 criminal misdemeanor crime the governor had proposed. Possession of cannabis by people under the age of 21 would be punishable by a $25 fine and mandatory participation in a substance abuse treatment or education program or both. The governor had suggested treating underage possession as a class 1 misdemeanor, punishable with a mandatory minimum fine of $500 or 50 hours of community service, as well as the suspension of drivers licenses for at least six months. Existing medical cannabis operators could enter the adult-use market if they pay a $10 million licensing conversion fee. Cannabis businesses would have to establish labor peace agreements with workers. A legislative commission would be directed to study adding on-site consumption licenses and microbusiness cannabis event permits that would allow licensees to conduct sales at venues like farmers markets or pop-up locations. That provision was also included in the earlier legislation lawmakers passed but was suggested for deletion by the governor. Meanwhile, the governor signed several other reform bills this session—including measures to provide resentencing relief for people with past cannabis convictions, protect the parental rights of marijuana consumers and allow patients to access medical cannabis in hospitals. Read the analysis on Virginia marijuana penalty enforcement below: The post Marijuana Reform Advocates Push Virginia Governor To Remove Public Consumption Penalty Increase From Legalization Bill appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

White House pushes Congress on “fair treatment” for hemp; New fed report tracks state marijuana revenue; Poll: Pennsylvania voters back legalization Subscribe to receive Marijuana Moment’s newsletter in your inbox every weekday morning. It’s the best way to make sure you know which cannabis stories are shaping the day. Get our daily newsletter. Email address: Leave this field empty if you're human: Your support makes Marijuana Moment possible… Hold on, just one second before you read today’s news. Have you thought about giving some financial support to Marijuana Moment? If so, today would be a great day to contribute. We’re planning our reporting for the coming months and it would really help to know what kind of support we can count on. Check us out on Patreon and sign up to give $25/month today: https://www.patreon.com/marijuanamoment / TOP THINGS TO KNOW The White House sent a letter asking Congress to “ensure the fair treatment of hemp products” by “at a minimum” delaying a broad recriminalization law set to take effect in November—and citing a recent amendment that would’ve kept THC products legal while adding regulations. The Drug Enforcement Administration is resisting testimony during the marijuana rescheduling hearing set to start next week from an agency official linked to a report on the harms of cannabis use—and the prohibitionist organization Smart Approaches to Marijuana is seeking to select the DEA pharmacologist as its own witness. A Drug Enforcement Administration judge issued an order setting a detailed schedule for the marijuana rescheduling hearing starting next week—including when the designated participants can cross-examine the government’s witness and vice versa. The U.S. Census Bureau published an updated federal report showing that states have generated nearly $15 billion in marijuana tax revenue over the last almost five years. A new poll shows that three out of four Pennsylvania voters support legalizing marijuana—and that the largest share blame Republican lawmakers for the lack of progress on cannabis reform. U.S. Olympian and former Ironman 70.3 World Champion Joanna Zeiger writes in a new Marijuana Moment op-ed about how medical cannabis helps her deal with the effects of a cycling accident and how federal rescheduling can “help pave the way for more rational healthcare policies.” The Missouri State Highway Patrol said that “hundreds of thousands” of marijuana offenses may still exist on criminal records despite a deadline to clear them—though a court said there’s “no evidence to back up that estimate.” / FEDERAL Customs and Border Protection included stats about marijuana seizures in a list of “drug interdictions that save lives.” The Drug Enforcement Administration reportedly allowed hundreds of thousands of fentanyl pills to hit the streets of New Mexico. / STATES Wisconsin Democratic gubernatorial candidate Kelda Roys, currently a state senator, said she wants to legalize marijuana and use revenue to fund early childhood education, an initiative she calls “get baked for babies.” Tennessee lawmakers discussed the impact of federal marijuana rescheduling on state cannabis reform. Guam regulators approved the territory’s first permit to operate a cannabis establishment. Hawaii officials will begin enforcing hemp product restrictions on July 1. Oregon regulators are accepting applications to serve on a psilocybin testing rules advisory committee. The Colorado Hemp Advisory Committee will meet on Thursday. Michigan regulators will hold a hearing about proposed changes to marijuana rules on July 23. — Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments. Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. — / LOCAL Los Angeles, California officials sent a newsletter with various cannabis updates. / INTERNATIONAL The Irish legislature’s Joint Committee on Drugs Use recommended decriminalizing all drugs. / SCIENCE & HEALTH A study suggested that “legalization of recreational marijuana does not significantly change the rate of children presenting to the [emergency department] with positive drug screens.” A study of rats found that “cannabinoid-based interventions demonstrate significant therapeutic promise for [phantom limb pain], showing efficacy as both early and delayed treatments.” / ADVOCACY, OPINION & ANALYSIS A survey of military veterans found that 54 percent support the Department of Veterans Affairs providing or paying for psilocybin-assisted therapy and that 45 percent support it providing or paying for MDMA-assisted therapy if approved by the Food and Drug Administration. The Virginian-Pilot editorial board celebrated the passage of legislation to legalize recreational marijuana sales but criticized it being included in the budget. / BUSINESS Curaleaf International launched a medical cannabis training platform forUK healthcare professionals. / CULTURE Olympic skier Bode Miller was arrested for possessing psilocybin mushrooms. Make sure to subscribe to get Marijuana Moment’s daily dispatch in your inbox. Get our daily newsletter. Email address: Leave this field empty if you're human: Photo courtesy of Chris Wallis // Side Pocket Images. The post DEA’s interesting cannabis testimony stance for rescheduling hearing (Newsletter: June 25, 2026) appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

This sounds like an amazing initiative! It's so inspiring to see businesses like Canna Bella Lux not only succeed but also genuinely uplift marginalized communities. Speaking of efficiency, I've found that using tools like a CPS test helps me stay sharp and focused throughout the day, especially when multitasking.

Girl games encourage creativity by letting players design outfits, create stunning makeovers, and explore colorful worlds filled with endless possibilities.